Logarithm

WideOrbit Introduces Widespread Benefits in WO Network 2023

Retrieved on: 
Thursday, August 3, 2023
Automation, Canadian Tire money, Sydney Coordinated Adaptive Traffic System, SAN, Radio, Logarithm, Mobile phone, Video game

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- WideOrbit , a market leader in broadcast and network TV and radio inventory and revenue workflow management, today announced the latest release of WO Network , the company’s flagship network ad sales and commercial operations platform.

Key Points: 
  • SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- WideOrbit , a market leader in broadcast and network TV and radio inventory and revenue workflow management, today announced the latest release of WO Network , the company’s flagship network ad sales and commercial operations platform.
  • Highlights of WO Network 2023 benefits include:
    Direct Response (DR) Automation (Revisions): Import DR deal changes into existing WO Network Deals, improving the efficiency of importing DR Deals from an external partner
    “WO Network 2023 simplifies network ad sales and commercial operations with new features and enhancements that deliver revenue growth, cost savings, and improved efficiency to our cable and broadcast network customers,” says Susie Hedrick, WideOrbit President and Managing Director, Traffic Systems.
  • WO Network 2023 is now available for general release.
  • Please contact WideOrbit for more information on how to upgrade your existing version or to learn more about WO Network.

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Retrieved on: 
Wednesday, June 28, 2023
Logarithm, Central nervous system, Natural history, Probability, Neurodegenerative disease, IDMC, Food and Drug Administration, Skin, MECP2, Rett syndrome, CTA, SNAP, AAV, CNS, Compound muscle action potential, U.S. FDA, CHU, Regeneration, Data analysis, Visual acuity, GAN, DPM, HIV disease progression rates, Patient, CMAP, Child, FDA, UK, IND, LogMAR chart, Food, Safety, Disease, Peripheral nervous system, Pharmaceutical industry, Medical imaging, DALLAS, List of things named after Thomas Bayes

DALLAS, June 28, 2023 (GLOBE NEWSWIRE) --  Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced new data analyses for TSHA-120 in GAN and initial clinical observations for TSHA-102 in Rett syndrome. Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates. The webcast link can be accessed on the Events and Presentations section of Taysha’s website.

Key Points: 
  • Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates.
  • The webcast link can be accessed on the Events and Presentations section of Taysha’s website.
  • We’ve requested a formal FDA meeting to discuss these new developments to support a potential regulatory path forward for TSHA-120.
  • TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression.

GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®

Retrieved on: 
Wednesday, July 20, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Sequence, Logarithm, Vision, Incidence, Safety, Review, Mitochondrion, Eye, LHON, Union, Research, EMA, Mitochondrial disease, Systematic review, Visual acuity, Color, AAV, Leber's hereditary optic neuropathy, Natural history, Optogenetics, Severe cognitive impairment, Science Translational Medicine, Quality of life, European Medicines Agency, Pain, Field line, Year, Retina, Ophthalmology, CRR, ND4, Retinal ganglion cell, CHMP, Institute, MTS, Hospital, Medical device, Pharmaceutical industry, Vaccine, Medical imaging, Patient, LogMAR chart, N, Optic neuropathy

Year 5 values were the LogMAR readings nearest to 1,825 days post treatment recorded between 1,825 +/- 28 days post-treatment.

Key Points: 
  • Year 5 values were the LogMAR readings nearest to 1,825 days post treatment recorded between 1,825 +/- 28 days post-treatment.
  • Responder analyses at Year 5 indicate that improved BCVA was a benefit for a substantial proportion of the study participants.
  • Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset.
  • The primary objective is to assess the long-term safety of intravitreal LUMEVOQ administration up to 5 years post-treatment.

GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy

Retrieved on: 
Monday, January 24, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Sequence, Logarithm, Research, Eye, Severe cognitive impairment, EMA, European Medicines Agency, Science Translational Medicine, LHON, Pain, Mitochondrion, Year, Mitochondrial disease, Incidence, Union, ND4, MTS, Ophthalmology, Field line, Safety, Quality of life, Visual acuity, Institute, AAV, Leber's hereditary optic neuropathy, DNA, Review, Retina, Color, Vision, Systematic review, CRR, Optogenetics, Retinal ganglion cell, CHMP, Natural history, Medical device, Pharmaceutical industry, Medical imaging, Patient, N, Optic neuropathy, LogMAR chart, GenSight Biologics, Leber Hereditary Optic Neuropathy (LHON), LUMEVOQ® (GS010; lenadogene nolparvovec), RESCUE, REVERSE, and RESTORE, GENSIGHT BIOLOGICS, LEBER HEREDITARY OPTIC NEUROPATHY (LHON), LUMEVOQ® (GS010; LENADOGENE NOLPARVOVEC), RESCUE, REVERSE, AND RESTORE

Year 4 values were the LogMAR readings nearest to 1461 days post treatment recorded between 1461 +/- 273 days post- treatment.

Key Points: 
  • Year 4 values were the LogMAR readings nearest to 1461 days post treatment recorded between 1461 +/- 273 days post- treatment.
  • 71.0% of RESTORE subjects achieved Clinically Relevant Recovery (CRR)4 against nadir four years after treatment, and 80.7% of them had on-chart vision (BCVA 1.6 LogMAR) in one or both eyes.
  • Viewed against the trend in vision typically seen in untreated patients5, the findings represent a significant departure from the natural progression of LHON.
  • Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset.

IdentityMind Awarded New Patent on Using the Digital Identity Graph to Uncover Risk in Digital Transactions

Retrieved on: 
Tuesday, April 23, 2019
Computer access control, Digital identity, Digital technology, Federated identity, Identity, Identity management, Patent and Trademark Office, Logarithm, Information and communications technology, Abstraction, Logic

PALO ALTO, Calif., April 23, 2019 /PRNewswire-PRWeb/ -- IdentityMind, Digital Identities you Can Trust, announced today that the U.S. Patent and Trademark Office (USPTO) has granted IdentityMind a patent for utilizing features of its Identity Graph to yield a risk score -- "Graph Score" - to assess the risk of transactions performed by the digital identities represented in the graph.

Key Points: 
  • PALO ALTO, Calif., April 23, 2019 /PRNewswire-PRWeb/ -- IdentityMind, Digital Identities you Can Trust, announced today that the U.S. Patent and Trademark Office (USPTO) has granted IdentityMind a patent for utilizing features of its Identity Graph to yield a risk score -- "Graph Score" - to assess the risk of transactions performed by the digital identities represented in the graph.
  • IdentityMind's latest digital identity patent builds on the strength of IdentityMind's core Electronic DNA (eDNA) technology to further leverage digital identities to help protect financial transactions.
  • "The IdentityMind platform has been, from day one, built on digital identities," said Jose Caldera, IdentityMind's Chief Products and Marketing Officer.
  • "The combination of Graph Score and the eDNA reputation yields unprecedented accuracy in its assessment of the transaction risk associated with a specific digital identity.

Poppi Z Melera Launching Entertaining and Energizing Self-Help Book Psychological Warfare: The Power of Mental Strength and the Formula for Victory Nov 21st

Retrieved on: 
Wednesday, November 21, 2018
Behavior, Aggression, Crowd psychology, Mind control, Psychological warfare, Psychology, Logarithm

Psychological Warfare: The Power of Mental Strength and the Formula for Victory shows them how.

Key Points: 
  • Psychological Warfare: The Power of Mental Strength and the Formula for Victory shows them how.
  • THE AUTHOR Poppi Z Melera's first book is inspired by the challenges she faced and met on her two-decade rise to success in the rough-and-tumble world of energy markets.
  • Poppi is the founder and managing partner of The Z Firm ( www.zfirm-us.com ), a recruiting and staffing company specializing in the energy business.
  • Assigning editors and producers may request a review copy of Psychological Warfare: The Power of Mental Strength and the Formula for Victory.Author and book jacket art are available upon request.